Cargando…

UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line Xenografts

PURPOSE: In spite of advances in therapy for some subtypes, group 3 medulloblastoma continues to portend a poor prognosis. A subpopulation of medulloblastoma cells expressing the cell surface marker CD133 have been posited as possible stem cell like cancer cells (SCLCC), a potential source of drug r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Williams, Adele P., Garner, Evan F., Stafman, Laura L., Aye, Jamie M., Quinn, Colin H., Marayati, Raoud, Stewart, Jerry E., Atigadda, Venkatram R., Mroczek-Musulman, Elizabeth, Moore, Blake P., Beierle, Elizabeth A., Friedman, Gregory K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2019
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6664160/ https://www.ncbi.nlm.nih.gov/pubmed/31362265 http://dx.doi.org/10.1016/j.tranon.2019.07.003

Ejemplares similares

9-cis-UAB30, a novel rexinoid agonist, decreases tumorigenicity and cancer cell stemness of human neuroblastoma patient-derived xenografts
por: Marayati, Raoud, et al.
Publicado: (2020)

FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts
por: Garner, Evan F., et al.
Publicado: (2018)

PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells
por: Stafman, Laura L., et al.
Publicado: (2019)

EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth
por: Bownes, Laura V., et al.
Publicado: (2021)

The effects of focal adhesion kinase and platelet-derived growth factor receptor beta inhibition in a patient-derived xenograft model of primary and metastatic Wilms tumor
por: Aye, Jamie M., et al.
Publicado: (2019)

CRISPR/Cas9-mediated knockout of PIM3 suppresses tumorigenesis and cancer cell stemness in human hepatoblastoma cells
por: Marayati, Raoud, et al.
Publicado: (2022)

Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts
por: Stafman, Laura L., et al.
Publicado: (2019)

Downregulation of PDGFRß Signaling Overcomes Crizotinib Resistance in a TYRO3 and ALK Mutated Neuroendocrine-Like Tumor
por: Quinn, Colin H., et al.
Publicado: (2021)

The Role of PIM Kinases in Pediatric Solid Tumors
por: Julson, Janet Rae, et al.
Publicado: (2022)

Targeting Focal Adhesion Kinase Suppresses the Malignant Phenotype in Rhabdomyosarcoma Cells()
por: Waters, Alicia M., et al.
Publicado: (2016)

Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma
por: Bownes, Laura V., et al.
Publicado: (2022)

Immunotherapy in Pediatric Solid Tumors—A Systematic Review
por: Marayati, Raoud, et al.
Publicado: (2019)

PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma
por: Marayati, Raoud, et al.
Publicado: (2021)

Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma
por: Stafman, Laura L., et al.
Publicado: (2018)

Targeting High-Risk Neuroblastoma Patient-Derived Xenografts with Oncolytic Virotherapy
por: Quinn, Colin H., et al.
Publicado: (2022)

Serine-Threonine Kinase Receptor-Associated Protein (STRAP) Knockout Decreases the Malignant Phenotype in Neuroblastoma Cell Lines
por: Bownes, Laura V, et al.
Publicado: (2021)

Methyl Substitution of a Rexinoid Agonist Improves Potency and Reveals Site of Lipid Toxicity
por: Atigadda, Venkatram R., et al.
Publicado: (2014)

Rewiring Tumor Cell State in Cancer Therapy: Comment on ‘9-cis-UAB30, a Novel Rexinoid Agonist, Decreases Tumorigenicity and Cancer Cell Stemness of Human Neuroblastoma Patient-Derived Xenografts’ by ‘Elizabeth Beierle et al.’
por: Chakraborty, Abhishek A.
Publicado: (2020)

Investigation of PP2A and Its Endogenous Inhibitors in Neuroblastoma Cell Survival and Tumor Growth
por: Williams, Adele P., et al.
Publicado: (2018)

Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma()()
por: Stafman, Laura L., et al.
Publicado: (2018)

Adrenal extramedullary hematopoiesis in the setting of anti-Diego antibody and congenital dyserythropoietic anemia
por: Julson, Janet Rae, et al.
Publicado: (2022)

The socio-environmental Heritage of the UAB campus /
Publicado: (2006)

Rapid Characterization of Solid Tumors Using Resonant Sensors
por: Beierle, Andee M., et al.
Publicado: (2022)

Cell Proliferation in Neuroblastoma
por: Stafman, Laura L., et al.
Publicado: (2016)

Using 3D-bioprinted models to study pediatric neural crest-derived tumors
por: Quinn, Colin H, et al.
Publicado: (2023)

Oral retinoids and rexinoids in cutaneous T-cell lymphomas
por: Sokołowska-Wojdyło, Małgorzata, et al.
Publicado: (2013)

Analysis of differential secondary effects of novel rexinoids: select rexinoid X receptor ligands demonstrate differentiated side effect profiles
por: Marshall, Pamela A, et al.
Publicado: (2015)

Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts
por: Lipner, Matthew B., et al.
Publicado: (2016)

Dataset on the response of Hut78 cells to novel rexinoids
por: Hackney Price, Jennifer, et al.
Publicado: (2018)

Underactive Bladder; Review of Progress and Impact From the International CURE-UAB Initiative
por: Chancellor, Michael B., et al.
Publicado: (2020)

The “Phantom Effect” of the Rexinoid LG100754: Structural and Functional Insights
por: Sato, Yoshiteru, et al.
Publicado: (2010)

Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Neuroblastoma
por: Gillory, Lauren A., et al.
Publicado: (2013)

Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Pediatric Solid Tumors
por: Megison, Michael L., et al.
Publicado: (2014)

Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma()
por: Waters, Alicia M., et al.
Publicado: (2016)

Multi-Omics Approach to Dissect the Mechanisms of Rexinoid Signaling in Myoblast Differentiation
por: Khilji, Saadia, et al.
Publicado: (2021)

The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice
por: Li, Y, et al.
Publicado: (2008)

Complex effects of rexinoids on ligand dependent activation or inhibition of the xenobiotic receptor, CAR
por: Tzameli, Iphigenia, et al.
Publicado: (2003)

The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer
por: Moerland, Jessica A., et al.
Publicado: (2020)

The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer
por: Reich, Lyndsey A., et al.
Publicado: (2022)

Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer
por: Anderson, Marybeth, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hjgnloqdo16lunefrecd14c2ea